Atomo Diagnostics Advances Australia-Wide HIV Self-Test Kit Rollout; Shares Rise 4%

MT Newswires Live06-12

Atomo Diagnostics (ASX:AT1) advanced the Australia-wide rollout of its HIV self-test kit supported by both federal and state governments, according to a Wednesday filing with the Australian bourse.

The diagnostic firm expects to record over AU$1.3 million in revenue over two years from the scale-up of the national HIV self-test mail-out program operated by the National Association of People with HIV Australia with funding commitment from the federal government, the filing said.

Further, Atomo will expand its test-kit vending machine currently under a pilot program in South Australia to 70 machines nationwide from the current six machines in partnership with Thorne Harbour Health, the filing added.

As per the filing, the company also signed a deal to provide the tests to support NSW Health’s MyTest pilot project via vending machines.

Shares of Atomo Diagnostic rose 4% in recent trade.

Price (AUD): $0.03, Change: $, Percent Change: +3.57%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment